A pre-planned feasibility analysis (based on run-in data from 2253 participants across all tumour cohorts), suggested that aspirin is well-tolerated after radical therapy, with a low burden of toxicity across all tumour groups (13/2253, 0.6% had CTCAE grade 3/4 symptoms). This data has now been published in The Lancet Gastroenterology and Hepatology and can be found here.
COVID-19 pandemic: Guidance for Add-Aspirin participants
In the current pandemic situation, we know that trial participants may have concerns or questions about taking their trial treatment and attending follow-up appointments. We have provided some general guidance here.
Add-Aspirin
Can taking daily aspirin after treatment for cancer stop or delay the cancer from coming back?
Welcome to Add-Aspirin
This website is designed to provide information about the Add-Aspirin Trial, both for people taking part in the trial (participants) and collaborators. Please use the menus at the top of the screen to find out more about the trial.
Add-Aspirin is a large randomised clinical trial, which is taking place in the UK, Republic of Ireland and India. It will recruit 11,000 participants to help find out whether regular aspirin use after treatment for an early stage cancer can prevent the cancer from coming back and preventing deaths.
Congratulations to our top 5 recruiting centres:
- University Hospitals Coventry & Warwickshire
- Tata Memorial Hospital, Mumbai
- Worcestershire Royal Hospital
- Royal Marsden Hospitals
- Queen Elizabeth Hospital, King's Lynn
*FOR GENERAL AND CLINICAL QUERIES, PLEASE CHECK OUR FAQs*
News
Add-Aspirin Feasibility Data Published
Quick Links
From Monday 16th March 2020, to RANDOMISE a participant from the UK please call +44 (0)20 7670 4925, rather than the usual randomisation line.
To RANDOMISE a participant from Republic of Ireland or India only, please use the 'Register a participant' link above to randomise online. Please make sure to press 'Randomise' once logged in to the server.
Unblind a participant in the UK
Breast
We aim to recruit 3100 individuals who have had surgery to remove an early stage breast cancer.
CURRENT STATUS:
OPEN
Detailed eligibility criteria available here
Top recruiters: Tata Memorial Hospital Mumbai, Western General Hospital, Worcestershire Royal Hospital, Churchill Hospital Oxford
PARTICIPANTS REGISTERED: 3695
PARTICIPANTS RANDOMISED: 3106
Colon/Rectum
We aim to to recruit 2600 individuals who have had surgery to remove an early stage bowel cancer.
CURRENT STATUS:
OPEN
Detailed eligibility criteria available here
Top recruiters: St James 's University Hospital, Western General Hospital, Bristol Haematology & Oncology Centre, Velindre Hospital
PARTICIPANTS REGISTERED: 2219
PARTICIPANTS RANDOMISED: 1827
Gastro
We aim to recruit 2100 individuals who have had surgery or a combination of chemotherapy and radiotherapy to treat a cancer of the stomach or oesophagus (food pipe).
CURRENT STATUS:
OPEN
Detailed eligibility criteria available here
Top recruiters: Tata Memorial Hospital Mumbai, Christie Hospital, Cancer Institute (WIA), UHCW, St James's University Hospital
PARTICIPANTS REGISTERED: 477
PARTICIPANTS RANDOMISED: 383
Prostate
We aim to recruit 2120 individuals who have had surgery or radiotherapy to treat an early stage prostate cancer.
CURRENT STATUS:
OPEN
Detailed eligibility criteria available here
Top recruiters: UHCW, Darent Valley Hospital, Queen Elizabeth Hospital King's Lynn, University Hospital of Wales
PARTICIPANTS REGISTERED: 1790
PARTICIPANTS RANDOMISED: 1529
the trial is being jointly funded by
